Resveratrol for Protein Folding Support
Resveratrol has repeatedly failed to reproduce its promising preclinical results in humans.
Overview
Verdict
How It Works
Dosing & Protocol
Typical dose
- Recommended dose
- Not recommended
- Expected timeframe
- n/a
Protocol
- form
- Not applicable
- duration
- Not applicable
- co factor
- Evidence indicates no demonstrated effect. Preclinical work shows resveratrol influences proteostasis pathways in models - inducing heat shock proteins, activating autophagy through AMPK and mTOR signalling, and reducing aggregation of amyloid-beta, alpha-synuclein and polyglutamine proteins in cell culture and in worm and fly models of proteinopathy. This is genuinely interesting cell biology. No human study has measured chaperone expression, autophagic flux, protein aggregation or any proteostasis endpoint after resveratrol, and the one substantial clinical trial in a proteinopathy - the 12-month Alzheimer disease trial at up to 1,000 mg twice daily - found no clinical benefit and greater brain volume loss in the treated arm.
- titration
- Not applicable
- starting dose
- Not applicable. No human trial has assessed protein folding, chaperone function or proteostasis after resveratrol
Evidence
What the studies say
No studies are yet linked to both Resveratrol and Protein Folding Support.
Safety
Caveats
May reduce training adaptations and interacts with several medications.
Less likely to help if
Medical Disclaimer
The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.
Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.